No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Immunity to : Implications for Vaccine Development

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
  • Author: Richard A. Proctor1
  • Editors: Vincent A. Fischetti2, Richard P. Novick3, Joseph J. Ferretti4, Daniel A. Portnoy5, Miriam Braunstein6, Julian I. Rood7
    Affiliations: 1: University of Wisconsin, Medical Microbiology/Immunology, Madison, WI 53705; 2: The Rockefeller University, New York, NY; 3: Skirball Institute for Molecular Medicine, NYU Medical Center, New York, NY; 4: Department of Microbiology & Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK; 5: Department of Molecular and Cellular Microbiology, University of California, Berkeley, Berkeley, CA; 6: Department of Microbiology and Immunology, University of North Carolina-Chapel Hill, Chapel Hill, NC; 7: Infection and Immunity Program, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Australia
  • Source: microbiolspec July 2019 vol. 7 no. 4 doi:10.1128/microbiolspec.GPP3-0037-2018
  • Received 27 July 2018 Accepted 01 November 2018 Published 12 July 2019
  • Richard A. Proctor, [email protected]
image of Immunity to <span class="jp-italic">Staphylococcus aureus</span>: Implications for Vaccine Development
    Preview this microbiology spectrum article:
    Zoom in

    Immunity to : Implications for Vaccine Development, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/7/4/GPP3-0037-2018-1.gif /docserver/preview/fulltext/microbiolspec/7/4/GPP3-0037-2018-2.gif
  • Abstract:

    Cell-mediated immunity seems to be critical for prevention and resolution of invasive infections, but an imbalance in this immunity may also produce SIRS and death or an inadequate protective response with prolonged bacteremia and death. This dysregulation is likely at the heart of mortality and severe disease in humans. Anti-toxin antibodies may also come into play in reducing the severity of infections, but these antibodies might also address superantigen-induced immune dysregulation. Thus, while changing intrinsic T cell responses may be therapeutically difficult, monoclonal antibodies against superantigens may have utility in addressing dysfunctional immune responses to . The models above are hypotheses for examining, and potentially dramatically improving immune response to and safety of vaccines.

  • Citation: Proctor R. 2019. Immunity to : Implications for Vaccine Development. Microbiol Spectrum 7(4):GPP3-0037-2018. doi:10.1128/microbiolspec.GPP3-0037-2018.


1. Fowler VG Jr, Proctor RA. 2014. Where does a Staphylococcus aureus vaccine stand? Clin Microbiol Infect 20(Suppl 5) :66–75 http://dx.doi.org/10.1111/1469-0691.12570. [PubMed]
2. Proctor RA. 2012. Is there a future for a Staphylococcus aureus vaccine? Vaccine 30:2921–2927 http://dx.doi.org/10.1016/j.vaccine.2011.11.006. [PubMed]
3. Proctor RA. 2012. Challenges for a universal Staphylococcus aureus vaccine. Clin Infect Dis 54:1179–1186 http://dx.doi.org/10.1093/cid/cis033. [PubMed]
4. Proctor RA. 2015. Recent developments for Staphylococcus aureus vaccines: clinical and basic science challenges. Eur Cell Mater 30:315–326 http://dx.doi.org/10.22203/eCM.v030a22. [PubMed]
5. Kolata JB, Kühbandner I, Link C, Normann N, Vu CH, Steil L, Weidenmaier C, Bröker BM. 2015. The fall of a dogma? Unexpected high T-cell memory response to Staphylococcus aureus in humans. J Infect Dis 212:830–838 http://dx.doi.org/10.1093/infdis/jiv128. [PubMed]
6. Salgado-Pabón W, Schlievert PM. 2014. Models matter: the search for an effective Staphylococcus aureus vaccine. Nat Rev Microbiol 12:585–591 http://dx.doi.org/10.1038/nrmicro3308. [PubMed]
7. Daum RS, Spellberg B. 2012. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis 54:560–567 http://dx.doi.org/10.1093/cid/cir828. [PubMed]
8. de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M, Feinberg J, von Bernuth H, Samarina A, Jannière L, Fieschi C, Stéphan JL, Boileau C, Lyonnet S, Jondeau G, Cormier-Daire V, Le Merrer M, Hoarau C, Lebranchu Y, Lortholary O, Chandesris MO, Tron F, Gambineri E, Bianchi L, Rodriguez-Gallego C, Zitnik SE, Vasconcelos J, Guedes M, Vitor AB, Marodi L, Chapel H, Reid B, Roifman C, Nadal D, Reichenbach J, Caragol I, Garty BZ, Dogu F, Camcioglu Y, Gülle S, Sanal O, Fischer A, Abel L, Stockinger B, Picard C, Casanova JL. 2008. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med 205:1543–1550 http://dx.doi.org/10.1084/jem.20080321. [PubMed]
9. Joshi A, Pancari G, Cope L, Bowman EP, Cua D, Proctor RA, McNeely T. 2012. Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum Vaccin Immunother 8:336–346 http://dx.doi.org/10.4161/hv.18946. [PubMed]
10. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, Fulcher DA, Tangye SG, Cook MC. 2008. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 205:1551–1557 http://dx.doi.org/10.1084/jem.20080218. [PubMed]
11. Maher BM, Mulcahy ME, Murphy AG, Wilk M, O’Keeffe KM, Geoghegan JA, Lavelle EC, McLoughlin RM. 2013. Nlrp-3-driven interleukin 17 production by γδT cells controls infection outcomes during Staphylococcus aureus surgical site infection. Infect Immun 81:4478–4489 http://dx.doi.org/10.1128/IAI.01026-13. [PubMed]
12. Miller LS, Cho JS. 2011. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol 11:505–518 http://dx.doi.org/10.1038/nri3010. [PubMed]
13. Minegishi Y, Saito M, Nagasawa M, Takada H, Hara T, Tsuchiya S, Agematsu K, Yamada M, Kawamura N, Ariga T, Tsuge I, Karasuyama H. 2009. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med 206:1291–1301 http://dx.doi.org/10.1084/jem.20082767. [PubMed]
14. Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, Lorenzo L, Mamani-Matsuda M, Jouanguy E, Gendrel D, Casanova JL. 2008. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol 180:647–654 http://dx.doi.org/10.4049/jimmunol.180.1.647. [PubMed]
15. Thomason J, Rentsch C, Stenehjem EA, Hidron AI, Rimland D. 2015. Association between vitamin D deficiency and methicillin-resistant Staphylococcus aureus infection. Infection 43:715–722 http://dx.doi.org/10.1007/s15010-015-0815-5. [PubMed]
16. Wang JW, Hogan PG, Hunstad DA, Fritz SA. 2015. Vitamin D sufficiency and Staphylococcus aureus infection in children. Pediatr Infect Dis J 34:544–545 http://dx.doi.org/10.1097/INF.0000000000000667. [PubMed]
17. van der Does AM, Kenne E, Koppelaar E, Agerberth B, Lindbom L. 2014. Vitamin D 3 and phenylbutyrate promote development of a human dendritic cell subset displaying enhanced antimicrobial properties. J Leukoc Biol 95:883–891 http://dx.doi.org/10.1189/jlb.1013549. [PubMed]
18. O’Keeffe KM, Wilk MM, Leech JM, Murphy AG, Laabei M, Monk IR, Massey RC, Lindsay JA, Foster TJ, Geoghegan JA, McLoughlin RM. 2015. Manipulation of autophagy in phagocytes facilitates Staphylococcus aureus bloodstream infection. Infect Immun 83:3445–3457 http://dx.doi.org/10.1128/IAI.00358-15. [PubMed]
19. Hepburn L, Prajsnar TK, Klapholz C, Moreno P, Loynes CA, Ogryzko NV, Brown K, Schiebler M, Hegyi K, Antrobus R, Hammond KL, Connolly J, Ochoa B, Bryant C, Otto M, Surewaard B, Seneviratne SL, Grogono DM, Cachat J, Ny T, Kaser A, Török ME, Peacock SJ, Holden M, Blundell T, Wang L, Ligoxygakis P, Minichiello L, Woods CG, Foster SJ, Renshaw SA, Floto RA. 2014. Innate immunity. A Spaetzle-like role for nerve growth factor β in vertebrate immunity to Staphylococcus aureus. Science 346:641–646 http://dx.doi.org/10.1126/science.1258705. [PubMed]
20. Pacquelet S, Johnson JL, Ellis BA, Brzezinska AA, Lane WS, Munafo DB, Catz SD. 2007. Cross-talk between IRAK-4 and the NADPH oxidase. Biochem J 403:451–461 http://dx.doi.org/10.1042/BJ20061184. [PubMed]
21. Picard C, von Bernuth H, Ghandil P, Chrabieh M, Levy O, Arkwright PD, McDonald D, Geha RS, Takada H, Krause JC, Creech CB, Ku CL, Ehl S, Maródi L, Al-Muhsen S, Al-Hajjar S, Al-Ghonaium A, Day-Good NK, Holland SM, Gallin JI, Chapel H, Speert DP, Rodriguez-Gallego C, Colino E, Garty BZ, Roifman C, Hara T, Yoshikawa H, Nonoyama S, Domachowske J, Issekutz AC, Tang M, Smart J, Zitnik SE, Hoarau C, Kumararatne DS, Thrasher AJ, Davies EG, Bethune C, Sirvent N, de Ricaud D, Camcioglu Y, Vasconcelos J, Guedes M, Vitor AB, Rodrigo C, Almazán F, Méndez M, Aróstegui JI, Alsina L, et al. 2010. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) 89:403–425 http://dx.doi.org/10.1097/MD.0b013e3181fd8ec3. [PubMed]
22. Singh A, Zarember KA, Kuhns DB, Gallin JI. 2009. Impaired priming and activation of the neutrophil NADPH oxidase in patients with IRAK4 or NEMO deficiency. J Immunol 182:6410–6417 http://dx.doi.org/10.4049/jimmunol.0802512. [PubMed]
23. van Bruggen R, Drewniak A, Tool AT, Jansen M, van Houdt M, Geissler J, van den Berg TK, Chapel H, Kuijpers TW. 2010. Toll-like receptor responses in IRAK-4-deficient neutrophils. J Innate Immun 2:280–287 http://dx.doi.org/10.1159/000268288. [PubMed]
24. Tanaka T, Narazaki M, Kishimoto T. 2014. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6:a016295 http://dx.doi.org/10.1101/cshperspect.a016295. [PubMed]
25. Hunter CA, Jones SA. 2015. IL-6 as a keystone cytokine in health and disease. Nat Immunol 16:448–457 http://dx.doi.org/10.1038/ni.3153. [PubMed]
26. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, Fu Y, French SW, Edwards JE Jr, Spellberg B. 2009. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 5:e1000703 http://dx.doi.org/10.1371/journal.ppat.1000703. [PubMed]
27. Kimura A, Kishimoto T. 2010. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40:1830–1835 http://dx.doi.org/10.1002/eji.201040391. [PubMed]
28. Smigiel KS, Srivastava S, Stolley JM, Campbell DJ. 2014. Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol Rev 259:40–59 http://dx.doi.org/10.1111/imr.12170. [PubMed]
29. Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio CW, Santacruz N, Peterson DA, Stappenbeck TS, Hsieh CS. 2011. Peripheral education of the immune system by colonic commensal microbiota. Nature 478:250–254 http://dx.doi.org/10.1038/nature10434. [PubMed]
30. Bustamante J, Boisson-Dupuis S, Jouanguy E, Picard C, Puel A, Abel L, Casanova JL. 2008. Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases. Curr Opin Immunol 20:39–48 http://dx.doi.org/10.1016/j.coi.2007.10.005. [PubMed]
31. Mogensen TH. 2013. STAT3 and the hyper-IgE syndrome: clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. JAK-STAT 2:e23435 http://dx.doi.org/10.4161/jkst.23435. [PubMed]
32. Heyworth PG, Cross AR, Curnutte JT. 2003. Chronic granulomatous disease. Curr Opin Immunol 15:578–584 http://dx.doi.org/10.1016/S0952-7915(03)00109-2.
33. Choi SM, McAleer JP, Zheng M, Pociask DA, Kaplan MH, Qin S, Reinhart TA, Kolls JK. 2013. Innate Stat3-mediated induction of the antimicrobial protein Reg3γ is required for host defense against MRSA pneumonia. J Exp Med 210:551–561 http://dx.doi.org/10.1084/jem.20120260. [PubMed]
34. Crum-Cianflone N, Weekes J, Bavaro M. 2009. Recurrent community-associated methicillin-resistant Staphylococcus aureus infections among HIV-infected persons: incidence and risk factors. AIDS Patient Care STDS 23:499–502 http://dx.doi.org/10.1089/apc.2008.0240. [PubMed]
35. Manfredi R, Calza L, Chiodo F. 2002. Epidemiology and microbiology of cellulitis and bacterial soft tissue infection during HIV disease: a 10-year survey. J Cutan Pathol 29:168–172 http://dx.doi.org/10.1034/j.1600-0560.2002.290307.x. [PubMed]
36. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. 2009. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 11:R109 http://dx.doi.org/10.1186/ar2764. [PubMed]
37. Barrera-Vargas A, Gómez-Martín D, Merayo-Chalico J, Ponce-de-León A, Alcocer-Varela J. 2014. Risk factors for drug-resistant bloodstream infections in patients with systemic lupus erythematosus. J Rheumatol 41:1311–1316 http://dx.doi.org/10.3899/jrheum.131261. [PubMed]
38. Espígol-Frigolé G, Corbera-Bellalta M, Planas-Rigol E, Lozano E, Segarra M, García-Martínez A, Prieto-González S, Hernández-Rodríguez J, Grau JM, Rahman MU, Cid MC. 2013. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis 72:1481–1487 http://dx.doi.org/10.1136/annrheumdis-2012-201836. [PubMed]
39. Taylor AL, Llewelyn MJ, Rudak PT, Memarnejadian A, Szabo PA, Tun-Abraham ME, Rossjohn J, Corbett AJ, McCluskey J, McCormick JK, Lantz O, Hernandez-Alejandro R, Taylor AL, Llewelyn MJ. 2010. Superantigen-induced proliferation of human CD4+CD25- T cells is followed by a switch to a functional regulatory phenotype. J Immunol 185:6591–6598 http://dx.doi.org/10.4049/jimmunol.1002416. [PubMed]
40. Ussher JE, Klenerman P, Willberg CB. 2014. Mucosal-associated invariant T-cells: new players in anti-bacterial immunity. Front Immunol 5:450 http://dx.doi.org/10.3389/fimmu.2014.00450. [PubMed]
41. Gao Y, Williams AP. 2015. Role of innate T cells in anti-bacterial immunity. Front Immunol 2:302. [PubMed]
42. Napier RJ, Adams EJ, Gold MC, Lewinsohn DM. 2015. The role of mucosal associated Invariant T cells in antimicrobial immunity. Front Immunol 6:344 http://dx.doi.org/10.3389/fimmu.2015.00344. [PubMed]
43. Sandberg JK, Norrby-Teglund A, Leeansyah E. 2017. Bacterial deception of MAIT cells in a cloud of superantigen and cytokines. PLoS Biol 15:e2003167 http://dx.doi.org/10.1371/journal.pbio.2003167. [PubMed]
44. Xiao X, Cai J. 2017. Mucosal-associated invariant T cells: new insights into antigen recognition and activation. Front Immunol 8:1540 http://dx.doi.org/10.3389/fimmu.2017.01540. [PubMed]
45. Reantragoon R, Boonpattanaporn N, Corbett AJ, McCluskey J. 2016. Mucosal-associated invariant T cells in clinical diseases. Asian Pac J Allergy Immunol 34:3–10.
46. Grimaldi D, Le Bourhis L, Sauneuf B, Dechartres A, Rousseau C, Ouaaz F, Milder M, Louis D, Chiche JD, Mira JP, Lantz O, Pène F. 2014. Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections. Intensive Care Med 40:192–201 http://dx.doi.org/10.1007/s00134-013-3163-x. [PubMed]
47. Shaler CR, Choi J, Rudak PT, Memarnejadian A, Szabo PA, Tun-Abraham ME, Rossjohn J, Corbett AJ, McCluskey J, McCormick JK, Lantz O, Hernandez-Alejandro R, Haeryfar SMM. 2017. MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: defining a novel mechanism of superantigen-induced immunopathology and immunosuppression. PLoS Biol 15:e2001930 http://dx.doi.org/10.1371/journal.pbio.2001930. [PubMed]
48. Balkhi MY, Ma Q, Ahmad S, Junghans RP. 2015. T cell exhaustion and interleukin 2 downregulation. Cytokine 71:339–347 http://dx.doi.org/10.1016/j.cyto.2014.11.024. [PubMed]
49. Dusseaux M, Martin E, Serriari N, Péguillet I, Premel V, Louis D, Milder M, Le Bourhis L, Soudais C, Treiner E, Lantz O. 2011. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 117:1250–1259 http://dx.doi.org/10.1182/blood-2010-08-303339. [PubMed]
50. Lussow AR, MacDonald HR. 1994. Differential effects of superantigen-induced “anergy” on priming and effector stages of a T cell-dependent antibody response. Eur J Immunol 24:445–449 http://dx.doi.org/10.1002/eji.1830240227. [PubMed]
51. White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P. 1989. The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell 56:27–35 http://dx.doi.org/10.1016/0092-8674(89)90980-X.
52. Ramesh N, Horner A, Ahern D, Geha RS. 1995. Bacterial superantigens induce the proliferation of resting gamma/delta receptor bearing T cells. Immunol Invest 24:713–724 http://dx.doi.org/10.3109/08820139509060700. [PubMed]
53. Cho SN, Song CH, Jin J, Kim SH, Rha KS, Kim YM. 2014. Role of staphylococcal enterotoxin B on the differentiation of regulatory T cells in nasal polyposis. Am J Rhinol Allergy 28:e17–e24 http://dx.doi.org/10.2500/ajra.2014.28.3995. [PubMed]
54. Gagliani N, Amezcua Vesely MC, Iseppon A, Brockmann L, Xu H, Palm NW, de Zoete MR, Licona-Limón P, Paiva RS, Ching T, Weaver C, Zi X, Pan X, Fan R, Garmire LX, Cotton MJ, Drier Y, Bernstein B, Geginat J, Stockinger B, Esplugues E, Huber S, Flavell RA. 2015. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 523:221–225 http://dx.doi.org/10.1038/nature14452. [PubMed]
55. Ouyang W, Liao W, Luo CT, Yin N, Huse M, Kim MV, Peng M, Chan P, Ma Q, Mo Y, Meijer D, Zhao K, Rudensky AY, Atwal G, Zhang MQ, Li MO. 2012. Novel Foxo1-dependent transcriptional programs control T(reg) cell function. Nature 491:554–559 http://dx.doi.org/10.1038/nature11581. [PubMed]
56. Pandiyan P, Zhu J. 2015. Origin and function of pro-inflammaory regulatory T cells. Cytokine 76:13–24 http://dx.doi.org/10.1016/j.cyto.2015.07.005. [PubMed]
57. Zeng WP, McFarland MM, Zhou B, Holtfreter S, Flesher S, Cheung A, Mallick A. 2017. Staphylococcal enterotoxin A-activated regulatory T cells promote allergen-specific T H2 response to intratracheal allergen inoculation. J Allergy Clin Immunol 139:508–518.e4 http://dx.doi.org/10.1016/j.jaci.2016.04.033. [PubMed]
58. Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, Bubeck Wardenburg J, Hunstad DA. 2013. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin Infect Dis 56:1554–1561 http://dx.doi.org/10.1093/cid/cit123. [PubMed]
59. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG. 2013. In ammation and host response to injury, large scale collaborative research program. Genomic responses in mouse models poorly mimic human in ammatory diseases. Proc Natl Acad Sci U S A 110:3507–3512 http://dx.doi.org/10.1073/pnas.1222878110. [PubMed]
60. Spaulding AR, Lin YC, Merriman JA, Brosnahan AJ, Peterson ML, Schlievert PM. 2012. Immunity to Staphylococcus aureus secreted proteins protects rabbits from serious illnesses. Vaccine 30:5099–5109 http://dx.doi.org/10.1016/j.vaccine.2012.05.067. [PubMed]
61. Rasigade JP, Sicot N, Laurent F, Lina G, Vandenesch F, Etienne J. 2011. A history of Panton-Valentine leukocidin (PVL)-associated infection protects against death in PVL-associated pneumonia. Vaccine 29:4185–4186 http://dx.doi.org/10.1016/j.vaccine.2011.04.033. [PubMed]
62. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, Chan ISF, McNeely TB, Kartsonis NA, Guris D, Onorato MT, Smugar SS, DiNubile MJ, Sobanjo-ter Meulen A. 2013. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery. JAMA 309:1368–1378 http://dx.doi.org/10.1001/jama.2013.3010. [PubMed]
63. McNeely TB, Shah NA, Fridman A, Joshi A, Hartzel JS, Keshari RS, Lupu F, DiNubile MJ. 2014. Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors. Hum Vaccin Immunother 10:3513–3516 http://dx.doi.org/10.4161/hv.34407. [PubMed]
64. Humrich JY, Riemekasten G. 2016. Restoring regulation: IL-2 therapy in systemic lupus erythematosus. Expert Rev Clin Immunol 12:1153–1160 http://dx.doi.org/10.1080/1744666X.2016.1199957. [PubMed]
65. Gupta DL, Bhoi S, Mohan T, Galwnkar S, Rao DN. 2016. Coexistence of Th1/Th2 and Th17/Treg imbalances in patients with post traumatic sepsis. Cytokine 88:214–221 http://dx.doi.org/10.1016/j.cyto.2016.09.010. [PubMed]
66. Minejima E, Bensman J, She RC, Mack WJ, Tuan Tran M, Ny P, Lou M, Yamaki J, Nieberg P, Ho J, Wong-Beringer A. 2016. A dysregulated balance of proinflammatory and anti-inflammatory host cytokine response early during therapy predicts persistence and mortality in Staphylococcus aureus bacteremia. Crit Care Med 44:671–679. [PubMed]
67. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frölich M. 1998. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 351:950–953 http://dx.doi.org/10.1016/S0140-6736(05)60606-X.
68. Rose WE, Eickhoff JC, Shukla SK, Pantrangi M, Rooijakkers S, Cosgrove SE, Nizet V, Sakoulas G. 2012. Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. J Infect Dis 206:1604–1611 http://dx.doi.org/10.1093/infdis/jis552. [PubMed]
69. Rose WE, Shukla SK, Berti AD, Hayney MS, Henriquez KM, Ranzoni A, Cooper MA, Proctor RA, Nizet V, Sakoulas G. 2017. Increased endovascular Staphylococcus aureus inoculum is the link between elevated serum interleukin 10 concentrations and mortality in patients with bacteremia. Clin Infect Dis 64:1406–1412 http://dx.doi.org/10.1093/cid/cix157. [PubMed]
70. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, Monticelli S, Lanzavecchia A, Sallusto F. 2012. Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 484:514–518 http://dx.doi.org/10.1038/nature10957. [PubMed]
71. Crispín JC, Tsokos GC. 2009. Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmun Rev 8:190–195 http://dx.doi.org/10.1016/j.autrev.2008.07.042. [PubMed]
72. Boyman O, Kolios AG, Raeber ME. 2015. Modulation of T cell responses by IL-2 and IL-2 complexes. Clin Exp Rheumatol 33(Suppl 92) :S54–S57.
73. Chapman NM, Bilal MY, Cruz-Orcutt N, Knudson C, Madinaveitia S, Light J, Houtman JC. 2013. Distinct signaling pathways regulate TLR2 co-stimulatory function in human T cells. Cell Signal 25:639–650 http://dx.doi.org/10.1016/j.cellsig.2012.11.026. [PubMed]
74. Chau TA, McCully ML, Brintnell W, An G, Kasper KJ, Vinés ED, Kubes P, Haeryfar SM, McCormick JK, Cairns E, Heinrichs DE, Madrenas J. 2009. Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate superantigen-induced T cell activation and prevent toxic shock syndrome. Nat Med 15:641–648 http://dx.doi.org/10.1038/nm.1965. [PubMed]
75. Li Z, Levast B, Madrenas J. 2017. Staphylococcus aureus downregulates IP-10 production and prevents Th1 cell recruitment. J Immunol 198:1865–1874 http://dx.doi.org/10.4049/jimmunol.1601336. [PubMed]
76. Li Z, Peres AG, Damian AC, Madrenas J. 2015. Immunomodulation and disease tolerance to Staphylococcus aureus. Pathogens 4:793–815 http://dx.doi.org/10.3390/pathogens4040793. [PubMed]
77. Andrade EB, Alves J, Madureira P, Oliveira L, Ribeiro A, Cordeiro-da-Silva A, Correia-Neves M, Trieu-Cuot P, Ferreira P. 2013. TLR2-induced IL-10 production impairs neutrophil recruitment to infected tissues during neonatal bacterial sepsis. J Immunol 191:4759–4768 http://dx.doi.org/10.4049/jimmunol.1301752. [PubMed]
78. Leech JM, Lacey KA, Mulcahy ME, Medina E, McLoughlin RM. 2017. IL-10 plays opposing roles during Staphylococcus aureus systemic and localized infections. J Immunol 198:2352–2365 http://dx.doi.org/10.4049/jimmunol.1601018. [PubMed]
79. Martire-Greco D, Rodriguez-Rodrigues N, Landoni VI, Rearte B, Isturiz MA, Fernández GC. 2013. Interleukin-10 controls human peripheral PMN activation triggered by lipopolysaccharide. Cytokine 62:426–432 http://dx.doi.org/10.1016/j.cyto.2013.03.025. [PubMed]
80. Shibata Y, Foster LA, Kurimoto M, Okamura H, Nakamura RM, Kawajiri K, Justice JP, Van Scott MR, Myrvik QN, Metzger WJ. 1998. Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-gamma-inducing factors but enhances NK cell production of IFN-gamma. J Immunol 161:4283–4288.
81. Wang JE, Jørgensen PF, Almlöf M, Thiemermann C, Foster SJ, Aasen AO, Solberg R. 2000. Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. Infect Immun 68:3965–3970 http://dx.doi.org/10.1128/IAI.68.7.3965-3970.2000. [PubMed]
82. Brown AF, Leech JM, Rogers TR, McLoughlin RM. 2014. Staphylococcus aureus colonization: modulation of host immune response and impact on human vaccine design. Front Immunol 4:507 http://dx.doi.org/10.3389/fimmu.2013.00507. [PubMed]
83. Brown AF, Murphy AG, Lalor SJ, Leech JM, O’Keeffe KM, Mac Aogáin M, O’Halloran DP, Lacey KA, Tavakol M, Hearnden CH, Fitzgerald-Hughes D, Humphreys H, Fennell JP, van Wamel WJ, Foster TJ, Geoghegan JA, Lavelle EC, Rogers TR, McLoughlin RM. 2015. Memory Th1 cells are protective in invasive Staphylococcus aureus infection. PLoS Pathog 11:e1005226 http://dx.doi.org/10.1371/journal.ppat.1005226. [PubMed]
84. Söderquist B, Sundqvist KG, Vikerfors T. 1992. Kinetics of serum levels of interleukin-6 in Staphylococcus aureus septicemia. Scand J Infect Dis 24:607–612 http://dx.doi.org/10.3109/00365549209054646. [PubMed]
85. McNicholas S, Talento AF, O’Gorman J, Hannan MM, Lynch M, Greene CM, Humphreys H, Fitzgerald-Hughes D. 2014. Cytokine responses to Staphylococcus aureus bloodstream infection differ between patient cohorts that have different clinical courses of infection. BMC Infect Dis 14:580 http://dx.doi.org/10.1186/s12879-014-0580-6. [PubMed]
86. Chantratita N, Tandhavanant S, Seal S, Wikraiphat C, Wongsuvan G, Ariyaprasert P, Suntornsut P, Teerawattanasook N, Jutrakul Y, Srisurat N, Chaimanee P, Mahavanakul W, Srisamang P, Phiphitaporn S, Mokchai M, Anukunananchai J, Wongratanacheewin S, Chetchotisakd P, Emond MJ, Peacock SJ, West TE. 2017. TLR4 genetic variation is associated with inflammatory responses in Gram-positive sepsis. Clin Microbiol Infect 23:47.e1–47.e10 http://dx.doi.org/10.1016/j.cmi.2016.08.028. [PubMed]
87. Jin JO, Zhang W, Du JY, Yu Q. 2014. BDCA1-positive dendritic cells (DCs) represent a unique human myeloid DC subset that induces innate and adaptive immune responses to Staphylococcus aureus infection. Infect Immun 82:4466–4476 http://dx.doi.org/10.1128/IAI.01851-14. [PubMed]
88. Karauzum H, Haudenschild CC, Moore IN, Mahmoudieh M, Barber DL, Datta SK. 2017. Lethal CD4 T cell responses induced by vaccination against Staphylococcus aureus bacteremia. J Infect Dis 215:1231–1239 http://dx.doi.org/10.1093/infdis/jix096. [PubMed]
89. Koymans KJ, Feitsma LJ, Brondijk TH, Aerts PC, Lukkien E, Lössl P, van Kessel KP, de Haas CJ, van Strijp JA, Huizinga EG. 2015. Structural basis for inhibition of TLR2 by staphylococcal superantigen-like protein 3 (SSL3). Proc Natl Acad Sci U S A 112:11018–11023 http://dx.doi.org/10.1073/pnas.1502026112. [PubMed]
90. Koymans KJ, Vrieling M, Gorham RD Jr, van Strijp JAG. 2017. Staphylococcal immune evasion proteins: structure, function, and host adaptation. Curr Top Microbiol Immunol 409:441–489 http://dx.doi.org/10.1007/82_2015_5017. [PubMed]
91. Nagelkerken L, Gollob KJ, Tielemans M, Coffman RL. 1993. Role of transforming growth factor-beta in the preferential induction of T helper cells of type 1 by staphylococcal enterotoxin B. Eur J Immunol 23:2306–2310 http://dx.doi.org/10.1002/eji.1830230938. [PubMed]
92. Niedergang F, Hémar A, Hewitt CR, Owen MJ, Dautry-Varsat A, Alcover A. 1995. The Staphylococcus aureus enterotoxin B superantigen induces specific T cell receptor down-regulation by increasing its internalization. J Biol Chem 270:12839–12845 http://dx.doi.org/10.1074/jbc.270.21.12839. [PubMed]
93. Stach CS, Herrera A, Schlievert PM. 2014. Staphylococcal superantigens interact with multiple host receptors to cause serious diseases. Immunol Res 59:177–181 http://dx.doi.org/10.1007/s12026-014-8539-7. [PubMed]
94. Szabo PA, Goswami A, Mazzuca DM, Kim K, O’Gorman DB, Hess DA, Welch ID, Young HA, Singh B, McCormick JK, Haeryfar SM. 2017. Rapid and rigorous IL-17A production by a distinct subpopulation of effector memory T lymphocytes constitutes a novel mechanism of toxic shock syndrome immunopathology. J Immunol 198:2805–2818 http://dx.doi.org/10.4049/jimmunol.1601366. [PubMed]
95. Takahashi N, Hasegawa H, Komiyama M, Ohki T, Yada Y, Koike Y, Kawamata R, Honma Y, Momoi M. 2009. Selective excretion of anti-inflammatory cytokine interleukin-10 in a superantigen-inducing neonatal infectious disease. Cytokine 45:39–43 http://dx.doi.org/10.1016/j.cyto.2008.10.015. [PubMed]
96. Tuffs SW, James DBA, Bestebroer J, Richards AC, Goncheva MI, O’Shea M, Wee BA, Seo KS, Schlievert PM, Lengeling A, van Strijp JA, Torres VJ, Fitzgerald JR. 2017. The Staphylococcus aureus superantigen SElX is a bifunctional toxin that inhibits neutrophil function. PLoS Pathog 13:e1006461 http://dx.doi.org/10.1371/journal.ppat.1006461. [PubMed]
97. Stolz SJ, Davis JP, Vergeront JM, Crass BA, Chesney PJ, Wand PJ, Bergdoll MS. 1985. Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin. J Infect Dis 151:883–889 http://dx.doi.org/10.1093/infdis/151.5.883. [PubMed]
98. Iwakura Y, Ishigame H, Saijo S, Nakae S. 2011. Functional specialization of interleukin-17 family members. Immunity 34:149–162 http://dx.doi.org/10.1016/j.immuni.2011.02.012. [PubMed]
99. Iwasaka H, Noguchi T. 2004. Th1/Th2 balance in systemic inflammatory response syndrome (SIRS). Nihon Rinsho 62:2237–2243. (In Japanese.)
100. Lacey KA, Geoghegan JA, McLoughlin RM. 2016. The role of Staphylococcus aureus virulence factors in skin infection and their potential as vaccine antigens. Pathogens 17:E22. [PubMed]
101. Frodermann V, Chau TA, Sayedyahossein S, Toth JM, Heinrichs DE, Madrenas J. 2011. A modulatory interleukin-10 response to staphylococcal peptidoglycan prevents Th1/Th17 adaptive immunity to Staphylococcus aureus. J Infect Dis 204:253–262 http://dx.doi.org/10.1093/infdis/jir276. [PubMed]
102. Donabedian H, Gallin JI. 1983. The hyperimmunoglobulin E recurrent-infection (Job’s) syndrome. A review of the NIH experience and the literature. Medicine (Baltimore) 62:195–208 http://dx.doi.org/10.1097/00005792-198307000-00001. [PubMed]

Article metrics loading...



Cell-mediated immunity seems to be critical for prevention and resolution of invasive infections, but an imbalance in this immunity may also produce SIRS and death or an inadequate protective response with prolonged bacteremia and death. This dysregulation is likely at the heart of mortality and severe disease in humans. Anti-toxin antibodies may also come into play in reducing the severity of infections, but these antibodies might also address superantigen-induced immune dysregulation. Thus, while changing intrinsic T cell responses may be therapeutically difficult, monoclonal antibodies against superantigens may have utility in addressing dysfunctional immune responses to . The models above are hypotheses for examining, and potentially dramatically improving immune response to and safety of vaccines.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

Model for human immunity to based on immune defects and cytokines in sepsis.

Source: microbiolspec July 2019 vol. 7 no. 4 doi:10.1128/microbiolspec.GPP3-0037-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2

enterotoxin modifications of immune response.

Source: microbiolspec July 2019 vol. 7 no. 4 doi:10.1128/microbiolspec.GPP3-0037-2018
Permissions and Reprints Request Permissions
Download as Powerpoint


Generic image for table

Immune defects that increase the incidence of infections

Source: microbiolspec July 2019 vol. 7 no. 4 doi:10.1128/microbiolspec.GPP3-0037-2018
Generic image for table

Cytokines, sepsis, and survival in infection

Source: microbiolspec July 2019 vol. 7 no. 4 doi:10.1128/microbiolspec.GPP3-0037-2018

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error